Replies to post #48108 on Amarantus Bioscience Holdings Inc (AMBS)

[smoke_em]

OK, fair enough, then tell us which projected PPS you trust, because a inferior drug to MANF, GDNF was bought for $270 million several years back? Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF, and is initially focusing on the development of MANF-based protein therapeutics. MANF's current lead indication is Parkinson's disease with additional focus on Traumatic Brain Injury (TBI). Future indications may include myocardial infarction and certain rare and ultra-rare orphan diseases where MANF is currently being evaluated.

http://finance.yahoo.com/news/amarantus-bioscience-announces-positive-efficacy-133100600.html

http://finance.yahoo.com/news/amarantus-bioscience-announces-publication-independent-133600183.html

How reliable is this source that recently upgraded AMBS with a 2.25 target by the fall of this year? The bios of the blog writers states the one guy used to write for Sierra Equity, which everyone knows is a complete joke.

Personally, I find this target hard to take seriously. Seems like an amateur blog and these guys just threw out a random price target based on nothing.

[StockDog OTC]

AMBS - Lets look past that source and see the Big picture here.

With the fundamentals here... couple dollars by fall is very possible and realistic!!

We have an Incredable company here and they Intend to up list to a National exchange. In order to do so, they need to maintain 2 dollar shares price for 90 days. Im sure they can do that!

MUST READ post on chairman’s blog:

http://www.thechairmansblog.com/gerald-commissiong/2012-12/manf-arresting-cell-death-in-parkinsons-disease-traumatic-brain-injury-cardiac-ischemia-and-more.html

“We just completed our first institutional capital raise and have attracted Big Pharma talent to our Advisory Board. We have data coming shortly on our MANF Parkinson’s program and expect additional corporate milestones will be reached in the coming weeks. As we achieve these milestones, we believe we will be in a good position to up-list to a national exchange.”


If you look back to the last time AMBS promised shareholders something moving forward (November 7th PR with 15, 30, 45 day milestones), they are pretty reliable at getting what they say they are going to do done. The CEO and employees are all shareholders themselves, so they are going to do everything in the best interest of this stock’s PPS.

Dr. Rubinfield, cofounder of AMGEN, I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson’s, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company’s new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug.”


This guy helped launch AMGEN from penny land to $80+ PPS. He’s 79 years old and has made millions and millions of dollars already. He has no incentive to go on record like this unless he truly believes in MANF, which he does.

http://www.forbes.com/profile/joseph-rubinfeld/


ALSO..... MANF is far superior to GDNF which was valed at 270 Million dollars! Soon MANF will be valued much Higher then 270 Mill. In my opinion...and Many others opinion as well

Complete History of GDNF can be found here:

http://www.pdpipeline.org/2011/GDNF/gdnf_table.htm